Psychosis is a complex and heterogeneous neuropsychiatric condition characterized by a loss of contact with reality, whose symptoms can include delusions and hallucinations. Episodic psychosis and altered cognitive function are major features of schizophrenia, a severe neurodevelopmental disorder that contributes significantly to the global burden of disease (Whiteford et al., 2013). Schizophrenia is highly heritable (Hilker et al., 2018; Sullivan et al., 2003) and recent genetic studies have indicated a complex polygenic architecture involving hundreds of genetic variants that individually confer a minimal increase on the overall risk of developing the disorder (Purcell et al., 2009). Large-scale genome-wide association studies (GWAS) have identified approximately 160 regions of the genome harboring common variants robustly associated with the diagnosis of schizophrenia, with evidence for a substantial polygenic component in signals that individually fall below genome-wide levels of significance (Pardiñas et al., 2018; Ripke et al., 2014). As the majority of schizophrenia-associated variants do not directly index coding changes affecting protein structure, there remains uncertainty about the causal genes involved in disease pathogenesis and how their function is dysregulated (Maurano et al., 2012).

A major hypothesis is that GWAS variants predominantly act to influence the regulation of gene expression. This hypothesis is supported by an enrichment of schizophrenia-associated variants in core regulatory domains (e.g., active promotors and enhancers) (Hannon et al., 2019a). As a consequence, there has been growing interest in the role of epigenetic variation in the molecular etiology of schizophrenia. DNA methylation is the best-characterized epigenetic modification, acting to influence gene expression via disruption of transcription factor binding and recruitment of methyl-binding proteins that initiate chromatin compaction and gene silencing. Despite being traditionally regarded as a mechanism of transcriptional repression, DNA methylation is actually associated with both increased and decreased gene expression (Wagner et al., 2014) and other genomic functions including alternative splicing and promoter usage (Maunakea et al., 2010). We previously demonstrated how DNA methylation is under local genetic control (Hannon et al., 2018a; Hannon et al., 2016b), identifying an enrichment of DNA methylation quantitative trait loci (mQTL) among genomic regions associated with schizophrenia (Hannon et al., 2016b). Furthermore, we have used mQTL associations to identify discrete sites of regulatory variation associated with schizophrenia risk variants implicating specific genes within these regions (Hannon et al., 2016a; Hannon et al., 2018a; Hannon et al., 2016b; Hannon et al., 2017). Of note, epigenetic variation induced by environmental exposures has been hypothesized as another mechanism by which non-genetic factors can affect risk for neuropsychiatric disorders including schizophrenia (Dempster et al., 2013).

The development of standardized assays for quantifying DNA methylation at specific sites across the genome has enabled the systematic analysis of associations between methylomic variation and environmental exposures or diseases (Murphy and Mill, 2014). Because DNA methylation is a dynamic process, these epigenome-wide association studies (EWAS) are more complex to design and interpret than GWAS (Mill and Heijmans, 2013; Rakyan et al., 2011; Relton and Davey Smith, 2010). As for observational epidemiological studies of exposures and outcomes, a number of potentially important confounding factors (e.g., tissue or cell type, age, sex, lifestyle exposures, medication, and disorder-associated exposures) that can directly influence DNA methylation need to be considered along with the possibility of reverse causation. Despite these difficulties, recent studies have identified schizophrenia-associated DNA methylation differences in analyses of post-mortem brain tissue (Jaffe et al., 2016; Pidsley et al., 2014; Viana et al., 2017; Wockner et al., 2014), and also detected disease-associated variation in peripheral blood samples from both schizophrenia-discordant monozygotic twin pairs (Dempster et al., 2011) and clinically ascertained case-control cohorts (Aberg et al., 2014; Hannon et al., 2016a; Kinoshita et al., 2014). We previously reported an EWAS of variable DNA methylation associated with schizophrenia in >1700 individuals, meta-analyzing data from three independent cohorts and identifying methylomic biomarkers of disease (Hannon et al., 2016a). Together these data support a role for differential DNA methylation in the molecular etiology of schizophrenia, although it is not clear whether disease-associated methylation differences are themselves secondary to the disorder itself or a result of other schizophrenia-associated factors.

In this study we extend our previous analysis, quantifying DNA methylation across the genome in a total of 4483 participants from seven independent case-control cohorts including patients with schizophrenia or first-episode psychosis (FEP) (Figure 1). This represents the largest EWAS of schizophrenia and psychosis, and one of the largest case-control studies of DNA methylation for any disease phenotype. In each cohort, genomic DNA was isolated from whole blood, and DNA methylation was quantified across the genome using either the Illumina Infinium HumanMethylation450 microarray (‘450K array’) or the HumanMethylationEPIC microarray (‘EPIC array’) (see 'Materials and methods'). We implemented a stringent pipeline to meta-analyze EWAS results across datasets to identify associations between psychosis cases and variation in DNA methylation. We show how DNA methylation data can be leveraged to identify biological (e.g., differential cell counts) and environmental (e.g., smoking) factors associated with psychosis, and present evidence for molecular variation associated with clozapine exposure in patients with treatment-resistant schizophrenia (TRS).

Figure 1 with 6 supplements see all

Download asset Open asset

We report the most comprehensive study of methylomic variation associated with psychosis and schizophrenia, profiling DNA methylation across the genome in peripheral blood samples from 2379 cases and 2104 controls. We show how DNA methylation data can be leveraged to derive measures of blood cell counts and smoking that are associated with psychosis. Using a stringent pipeline to meta-analyze EWAS results across datasets, we identify novel DMPs associated with both psychosis and a more refined diagnosis of schizophrenia. Of note, we show evidence for the colocalization of genetic associations for schizophrenia and differential DNA methylation. Finally, we present evidence for differential methylation associated with TRS, potentially reflecting differences in DNA methylation associated with exposure to the atypical antipsychotic drug clozapine.

We identify robust psychosis-associated differences in cellular composition estimates derived from DNA methylation data, with cases having increased proportions of monocytes and granulocytes and decreased proportions of natural killer cells, CD4⁺ T-cells and CD8⁺ T-cells, compared to non-psychiatric controls. This analysis extends previous work based on a subset of these data, which reported a decrease in the proportion of natural killer cells and increase in the proportion of granulocytes in schizophrenia patients, with the large number of samples enabling us to identify additional associations with other cell types. We also confirm findings from an independent study of schizophrenia which reported significantly increased proportions of granulocytes and monocytes, and decreased proportions of CD8⁺ T-cells using estimates derived from DNA methylation data (Montano et al., 2016). Of note, because we can only derive proportion of cell types from whole blood DNA methylation data, and not actual counts, an increase in one or more cell types must be balanced by a decrease in one or more other cell types and an apparent change in the proportion of one specific cell type does not mean that the actual abundance of that cell type is altered. Despite this, the results from DNA methylation-derived cell proportions are consistent with previous studies based on empirical cell abundance measures which have reported increased monocyte counts (Beumer et al., 2012; Moody and Miller, 2018), increased neutrophil counts (Garcia-Rizo et al., 2019; Núñez et al., 2019), increased monocyte-to-lymphocyte ratio (Mazza et al., 2020; Steiner et al., 2019), and increased neutrophil-to-lymphocyte ratio (Karageorgiou et al., 2019; Mazza et al., 2020) in both schizophrenia and FEP patients compared to controls. Previous studies have also shown that higher neutrophil counts in schizophrenia patients correlate with a greater burden of positive symptoms (Núñez et al., 2019) suggesting that variations in the number of neutrophils is a potential marker of disease severity (Steiner et al., 2019). Our sub-analysis of TRS, which is associated with a higher number of positive symptoms (Bachmann et al., 2017), found that the increase in granulocytes was primarily driven by those with the more severe phenotype, supporting this hypothesis. Importantly, the differences we observe may actually reflect the effects of various antipsychotic medications that have been previously shown to influence cell proportions in blood (Steiner et al., 2019) or a recruitment bias whereby patients with low levels of granulocytes are not prescribed clozapine given the risk of agranulocytosis.

We also identified a highly significant increase in a DNA methylation-derived smoking score in patients with schizophrenia, replicating our previous finding (Hannon et al., 2016a). The smoking score captures multiple aspects of tobacco smoking behavior including both current smoking status and the quantity of cigarettes smoked; our results therefore reflect existing epidemiological evidence demonstrating that schizophrenia patients not only smoke more, but also smoke more heavily (de Leon et al., 2002; de Leon and Diaz, 2005; McClave et al., 2010). We also report an increased smoking score in patients with FEP, although not to the same extent as seen in schizophrenia, consistent with a meta-analysis reporting high levels of smoking in FEP (Myles et al., 2012). In the subset of treatment-resistant patients, we found that there was an additional increase in smoking score relative to schizophrenia cases prescribed alternative medications, supporting evidence for higher rates of smoking in TRS groups relative to treatment-responsive schizophrenia patients (Kennedy et al., 2014). These results not only highlight physiological (i.e., cell proportions) and environmental (i.e., smoking) differences associated with psychosis and schizophrenia and the utility of DNA methylation data for deriving these variables in epidemiological studies, but also highlight the importance of controlling for these differences as potential confounders in analyses of disease-associated DNA methylation differences.

Our EWAS, building on our previous analysis on a subset of the sample cohorts profiled here (Hannon et al., 2016a), identified 95 DMPs associated with psychosis that are robust to differences in measured smoking exposure and heterogeneity in blood cellular composition derived from DNA methylation data. Of note, we identified a dramatic increase in sites characterized by an increase in DNA methylation in patients. A key strength of our study is the inclusion of the full spectrum of schizophrenia diagnoses, from FEP through to treatment-resistant cases prescribed clozapine. While this may introduce heterogeneity into our primary analyses, we used a random effects meta-analysis to identify consistent effects across all cohorts and diagnostic subtypes. We also performed an additional analysis focused specifically on cases with a more refined diagnosis of schizophrenia excluding those with FEP, which identified over 1000 DMPs. A number of the top-ranked DMPs are annotated to genes that have a direct relevance to the etiology of schizophrenia, and GO analysis highlighted multiple pathways previously implicated in schizophrenia, including several related to the extracellular matrix (Berretta, 2012) and cell-cell adhesion (O'Dushlaine et al., 2011). Given the known genetic component to the etiology of schizophrenia, it is interesting that schizophrenia-associated DMPs were found to colocalize to several regions nominated by genetic association studies. Our results suggest that this analysis of a more specific phenotype in a smaller number of samples is potentially more powerful and that schizophrenia cases have a more discrete molecular phenotype that might reflect both etiological factors but also factors associated with a diagnosis of schizophrenia (e.g., medications, stress, etc.). The mean difference in DNA methylation between cases and controls for both psychosis and schizophrenia was small, consistent with other blood-based EWAS of schizophrenia (Montano et al., 2016) and complex traits (Hannon et al., 2018c; Hannon et al., 2019b; Marioni et al., 2018) in general. While individually they may be too small to have a strong predictive power as a biomarker, together they may have utility as a molecular classifier (Chen et al., 2020).

To explore whether schizophrenia-associated differences in DNA methylation are present before a formal diagnosis of schizophrenia, we also performed an EWAS of individuals with FEP. Strikingly, the majority of our schizophrenia-associated DMPs were found to have a consistent direction of effect in the EWAS of individuals with FEP. While this result is consistent with schizophrenia-associated differences being present prior to a formal diagnosis of schizophrenia, it is not sufficient to state that they are causal; they may still reflect some underlying environmental risk factors or be a consequence of having FEP (e.g., medication exposure or other psychiatric condition). Further work is needed to explore the extent to which the DMPs associated with psychosis and schizophrenia in this meta-analysis might have a causal role in disease.

Finally, we also report the first systematic analysis of individuals with TRS, identifying seven DMPs at which differential DNA methylation was significantly different in the subset of schizophrenia cases prescribed clozapine. These data are informative for the interpretation of our schizophrenia-associated differences, because a number of these DMPs are driven by the subset of patients on clozapine. Furthermore, a number of sites show opposite effects in our analyses of TRS vs. our analysis of schizophrenia, suggesting they might represent important differences between diagnostic groups. Because the prescription of clozapine is generally only undertaken in patients with TRS, we are unable to separate the effects of clozapine exposure from differences associated with a more severe sub-type of schizophrenia such as the influence of polypharmaceutical treatment.

Our results should be considered in light of a number of important limitations. First, our analyses were constrained by the technical limitations of the Illumina 450K and EPIC arrays, which assay only ~ 3% of CpG sites in the genome. Second, this is a cross-sectional study and it was not possible to distinguish cause from effect. It is possible, and indeed likely, for example, that the differences associated with both schizophrenia and TRS reflect the effects of medication exposure or other consequences of having schizophrenia, for example, living more stressful lives, poorer diet, and health. The importance of such confounding variables is demonstrated by our findings of differential smoking score and blood cell proportions derived directly from the DNA methylation data, although these examples also highlight the potential utility of such effects for molecular epidemiology. Third, although our aim was not to make inferences about mechanistic changes in the brain associated with psychosis, it is important to note that our study analyzed DNA methylation profiled in peripheral blood and therefore can provide only limited information about variation in the primary tissue associated with disease (Hannon et al., 2015). Although this limits mechanistic conclusions about the role of DNA methylation in schizophrenia, biomarkers, by definition, need to be measured in an easily accessible tissue and do not need to reflect the underlying pathogenic process. Furthermore, because most classifiers used to quantify variables such as smoking exposure and age have been trained in blood, this represents the optimal tissue in which to derive these measures. Of course, blood may also be an appropriate choice for investigating medication effects, particularly given the known effects on white blood cell counts associated with taking clozapine (Alvir et al., 1993). Fourth, while we have explored the potential effects of clozapine on DNA methylation by assessing a sub-group of individuals with TRS, this is just one of a range of antipsychotics schizophrenia and psychosis patients are prescribed. The fact that the TRS group show more extreme differences for many of the schizophrenia-associated DMPs suggests that the polypharmaceutical treatment regimens often prescribed to schizophrenia patients may produce specific DNA methylation signatures in patients, akin to the effect seen for smoking. Fifth, although we found no evidence for a significant interaction between sex and DNA methylation at DMPs associated with schizophrenia, it is possible that there are other DNA methylation differences associated with disease only in males or females. Finally, although we found some evidence that schizophrenia-associated DMPs colocalize to regions nominated by GWAS, the integration of our DNA methylation data with genetic data was beyond the scope of this analysis. Of note, we have previously used mQTL associations to identify discrete sites of regulatory variation associated with schizophrenia risk variants to prioritize specific genes within broad GWAS regions (Hannon et al., 2016a; Hannon et al., 2018a; Hannon et al., 2016b; Hannon et al., 2017), and future work will aim to further explore interactions between genetic and epigenetic risk factors.

In conclusion, our analysis of 4483 participants represents the largest study of blood-based DNA methylation in schizophrenia and psychosis yet performed, and one of the largest EWAS studies for any disease phenotype. Our study also includes the first within-case analysis of TRS yet performed, providing important molecular insights into genomic differences associated with poor outcome to standard therapeutic approaches. Our results highlight differences in measures of blood cellular composition and smoking behavior derived from methylomic data between not just cases and controls, but also between TRS patients prescribed clozapine and those prescribed alternative medications. We report widespread differences in DNA methylation in psychosis and schizophrenia, a subset of which are driven by the more severe treatment-resistant subset of patients. On a practical level, our study not only demonstrates the utility of DNA methylation data for deriving measures of specific physiological phenotypes (e.g., blood cell-type proportions) and environmental exposures (e.g., exposure to tobacco smoke) that can be used to identify epidemiological associations with health and disease, but also highlights the importance of properly controlling for these potential confounders in EWAS analyses. Our results are important because they suggest there are also clear molecular signatures of schizophrenia and psychosis that can be identified in whole blood DNA. Although it is unlikely these differences are mechanistically related to neuropathological changes in the brain, they may have utility as diagnostic and prognostic biomarkers in individuals with FEP and may potentially be used to differentiate individuals with TRS at an early stage of disease. Future work should aim to prospectively profile DNA methylation in individuals at risk for FEP and schizophrenia to explore how methylomic variation at baseline can predict outcome and the extent to which longitudinal changes at psychosis-associated DMPs map on to clinical trajectories.

Raw and processed data for the UCL, Aberdeen and Dublin cohorts are available through GEO accession numbers GSE84727, GSE80417, and GSE147221, respectively.

1. 1. Hannon E
   2. Mill J

   (2020) NCBI Gene Expression Omnibus

   ID GSE147221. Blood DNA methylation profiles from schizophrenia cases and controls.

   https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147221

1. 1. Hannon E
   2. Dempster E
   3. Viana J
   4. Burrage J
   5. Smith AR
   6. Macdonald R
   7. St. Clair D
   8. Mustard C
   9. Breen G
   10. Therman S
   11. Kaprio J
   12. Toulopoulou T
   13. Hulshoff Pol HE
   14. Bohlken MM
   15. Kahn RS
   16. Nenadic I
   17. Hultman CM
   18. Murray RM
   19. Collier DA
   20. Bass N
   21. Gurling H
   22. McQuillin A
   23. Schalkwyk L
   24. Mill J

   (2016) NCBI Gene Expression Omnibus

   ID GSE80417. An integrated genetic-epigenetic analysis of schizophrenia: Evidence for co-localization of genetic associations and differential DNA methylation.

   https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80417
2. 1. Hannon E
   2. Dempster E
   3. Viana J
   4. Burrage J
   5. Smith AR
   6. Macdonald R
   7. St. Clair D
   8. Mustard C
   9. Breen G
   10. Therman S
   11. Kaprio J
   12. Toulopoulou T
   13. Hulshoff Pol HE
   14. Bohlken MM
   15. Kahn RS
   16. Nenadic I
   17. Hultman CM
   18. Murray RM
   19. Collier DA
   20. Bass N
   21. Gurling H
   22. McQuillin A
   23. Schalkwyk L
   24. Mill J

   (2016) NCBI Gene Expression Omnibus

   ID GSE84727. An integrated genetic-epigenetic analysis of schizophrenia: Evidence for co-localization of genetic associations and differential DNA methylation.

   https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84727

1. 1. Aberg KA
   2. McClay JL
   3. Nerella S
   4. Clark S
   5. Kumar G
   6. Chen W
   7. Khachane AN
   8. Xie L
   9. Hudson A
   10. Gao G
   11. Harada A
   12. Hultman CM
   13. Sullivan PF
   14. Magnusson PK
   15. van den Oord EJ

   (2014) Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults

   JAMA Psychiatry 71:255–264.

   https://doi.org/10.1001/jamapsychiatry.2013.3730

   • PubMed
   • Google Scholar
2. 1. Ajnakina O
   2. Horsdal HT
   3. Lally J
   4. MacCabe JH
   5. Murray RM
   6. Gasse C
   7. Wimberley T

   (2018) Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia

   Schizophrenia Research 197:294–297.

   https://doi.org/10.1016/j.schres.2018.02.017

   • PubMed
   • Google Scholar
3. 1. Aleman A
   2. Kahn RS
   3. Selten JP

   (2003) Sex differences in the risk of schizophrenia: evidence from meta-analysis

   Archives of General Psychiatry 60:565–571.

   https://doi.org/10.1001/archpsyc.60.6.565

   • PubMed
   • Google Scholar
4. 1. Alvir JM
   2. Lieberman JA
   3. Safferman AZ
   4. Schwimmer JL
   5. Schaaf JA

   (1993) Clozapine-induced agranulocytosis. incidence and risk factors in the united states

   New England Journal of Medicine 329:162–167.

   https://doi.org/10.1056/NEJM199307153290303

   • PubMed
   • Google Scholar
5. 1. Bachmann CJ
   2. Aagaard L
   3. Bernardo M
   4. Brandt L
   5. Cartabia M
   6. Clavenna A
   7. Coma Fusté A
   8. Furu K
   9. Garuoliené K
   10. Hoffmann F
   11. Hollingworth S
   12. Huybrechts KF
   13. Kalverdijk LJ
   14. Kawakami K
   15. Kieler H
   16. Kinoshita T
   17. López SC
   18. Machado-Alba JE
   19. Machado-Duque ME
   20. Mahesri M
   21. Nishtala PS
   22. Piovani D
   23. Reutfors J
   24. Saastamoinen LK
   25. Sato I
   26. Schuiling-Veninga CCM
   27. Shyu YC
   28. Siskind D
   29. Skurtveit S
   30. Verdoux H
   31. Wang LJ
   32. Zara Yahni C
   33. Zoëga H
   34. Taylor D

   (2017) International trends in clozapine use: a study in 17 countries

   Acta Psychiatrica Scandinavica 136:37–51.

   https://doi.org/10.1111/acps.12742

   • PubMed
   • Google Scholar
6. 1. Bebbington P
   2. Nayani T

   (1995)

   The psychosis screening questionnaire

   International Journal of Methods in Psychiatric Research 5:11–19.

   • Google Scholar
7. 1. Berretta S

   (2012) Extracellular matrix abnormalities in schizophrenia

   Neuropharmacology 62:1584–1597.

   https://doi.org/10.1016/j.neuropharm.2011.08.010

   • PubMed
   • Google Scholar
8. 1. Beumer W
   2. Gibney SM
   3. Drexhage RC
   4. Pont-Lezica L
   5. Doorduin J
   6. Klein HC
   7. Steiner J
   8. Connor TJ
   9. Harkin A
   10. Versnel MA
   11. Drexhage HA

   (2012) The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes

   Journal of Leukocyte Biology 92:959–975.

   https://doi.org/10.1189/jlb.0212100

   • PubMed
   • Google Scholar
9. 1. Brown MB

   (1975) 400: a method for combining Non-Independent, One-Sided tests of significance

   Biometrics 31:987–992.

   https://doi.org/10.2307/2529826

   • Google Scholar
10. 1. Chen J
    2. Zang Z
    3. Braun U
    4. Schwarz K
    5. Harneit A
    6. Kremer T
    7. Ma R
    8. Schweiger J
    9. Moessnang C
    10. Geiger L
    11. Cao H
    12. Degenhardt F
    13. Nöthen MM
    14. Tost H
    15. Meyer-Lindenberg A
    16. Schwarz E

    (2020) Association of a reproducible epigenetic risk profile for schizophrenia with brain methylation and function

    JAMA Psychiatry 77:628.

    https://doi.org/10.1001/jamapsychiatry.2019.4792

    • PubMed
    • Google Scholar
11. 1. Croissant Y
    2. Millo G

    (2008) Panel data econometrics in R: the plm package

    Journal of Statistical Software 2:i02.

    https://doi.org/10.18637/jss.v027.i02

    • Google Scholar
12. 1. Cross-Disorder Group of the Psychiatric Genomics Consortium

    (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis

    The Lancet 381:1371–1379.

    https://doi.org/10.1016/S0140-6736(12)62129-1

    • PubMed
    • Google Scholar
13. 1. Datta SR
    2. McQuillin A
    3. Rizig M
    4. Blaveri E
    5. Thirumalai S
    6. Kalsi G
    7. Lawrence J
    8. Bass NJ
    9. Puri V
    10. Choudhury K
    11. Pimm J
    12. Crombie C
    13. Fraser G
    14. Walker N
    15. Curtis D
    16. Zvelebil M
    17. Pereira A
    18. Kandaswamy R
    19. St Clair D
    20. Gurling HM

    (2010) A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia

    Molecular Psychiatry 15:615–628.

    https://doi.org/10.1038/mp.2008.128

    • PubMed
    • Google Scholar
14. Software

    1. Davis S
    2. Du P
    3. Bilke S
    4. Triche J
    5. Bootwalla M

    (2015)

    Methylumi: Handle Illumina Methylation Data, version R package version 2.14.0.

    Methylumi: Handle Illumina Methylation Data.
15. 1. de Leon J
    2. Becoña E
    3. Gurpegui M
    4. Gonzalez-Pinto A
    5. Diaz FJ

    (2002) The association between high nicotine dependence and severe mental illness may be consistent across countries

    The Journal of Clinical Psychiatry 63:812–816.

    https://doi.org/10.4088/JCP.v63n0911

    • PubMed
    • Google Scholar
16. 1. de Leon J
    2. Diaz FJ

    (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

    Schizophrenia Research 76:135–157.

    https://doi.org/10.1016/j.schres.2005.02.010

    • PubMed
    • Google Scholar
17. 1. Dempster EL
    2. Pidsley R
    3. Schalkwyk LC
    4. Owens S
    5. Georgiades A
    6. Kane F
    7. Kalidindi S
    8. Picchioni M
    9. Kravariti E
    10. Toulopoulou T
    11. Murray RM
    12. Mill J

    (2011) Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder

    Human Molecular Genetics 20:4786–4796.

    https://doi.org/10.1093/hmg/ddr416

    • PubMed
    • Google Scholar
18. 1. Dempster E
    2. Viana J
    3. Pidsley R
    4. Mill J

    (2013) Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future

    Schizophrenia Bulletin 39:11–16.

    https://doi.org/10.1093/schbul/sbs139

    • PubMed
    • Google Scholar
19. 1. Di Forti M
    2. Morgan C
    3. Dazzan P
    4. Pariante C
    5. Mondelli V
    6. Marques TR
    7. Handley R
    8. Luzi S
    9. Russo M
    10. Paparelli A
    11. Butt A
    12. Stilo SA
    13. Wiffen B
    14. Powell J
    15. Murray RM

    (2009) High-potency Cannabis and the risk of psychosis

    British Journal of Psychiatry 195:488–491.

    https://doi.org/10.1192/bjp.bp.109.064220

    • PubMed
    • Google Scholar
20. 1. Di Forti M
    2. Marconi A
    3. Carra E
    4. Fraietta S
    5. Trotta A
    6. Bonomo M
    7. Bianconi F
    8. Gardner-Sood P
    9. O'Connor J
    10. Russo M
    11. Stilo SA
    12. Marques TR
    13. Mondelli V
    14. Dazzan P
    15. Pariante C
    16. David AS
    17. Gaughran F
    18. Atakan Z
    19. Iyegbe C
    20. Powell J
    21. Morgan C
    22. Lynskey M
    23. Murray RM

    (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency Cannabis: a case-control study

    The Lancet Psychiatry 2:233–238.

    https://doi.org/10.1016/S2215-0366(14)00117-5

    • PubMed
    • Google Scholar
21. 1. Elliott HR
    2. Tillin T
    3. McArdle WL
    4. Ho K
    5. Duggirala A
    6. Frayling TM
    7. Davey Smith G
    8. Hughes AD
    9. Chaturvedi N
    10. Relton CL

    (2014) Differences in smoking associated DNA methylation patterns in south asians and europeans

    Clinical Epigenetics 6:4.

    https://doi.org/10.1186/1868-7083-6-4

    • PubMed
    • Google Scholar
22. 1. Garcia-Rizo C
    2. Casanovas M
    3. Fernandez-Egea E
    4. Oliveira C
    5. Meseguer A
    6. Cabrera B
    7. Mezquida G
    8. Bioque M
    9. Kirkpatrick B
    10. Bernardo M
    11. European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group

    (2019) Blood cell count in antipsychotic-naive patients with non-affective psychosis

    Early Intervention in Psychiatry 13:95–100.

    https://doi.org/10.1111/eip.12456

    • PubMed
    • Google Scholar
23. 1. Gaughran F
    2. Stahl D
    3. Stringer D
    4. Hopkins D
    5. Atakan Z
    6. Greenwood K
    7. Patel A
    8. Smith S
    9. Gardner-Sood P
    10. Lally J
    11. Heslin M
    12. Stubbs B
    13. Bonaccorso S
    14. Kolliakou A
    15. Howes O
    16. Taylor D
    17. Forti MD
    18. David AS
    19. Murray RM
    20. Ismail K
    21. The IMPACT team

    (2019) Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study

    British Journal of Psychiatry 215:712–719.

    https://doi.org/10.1192/bjp.2019.159

    • Google Scholar
24. 1. Hannon E
    2. Lunnon K
    3. Schalkwyk L
    4. Mill J

    (2015) Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes

    Epigenetics 10:1024–1032.

    https://doi.org/10.1080/15592294.2015.1100786

    • PubMed
    • Google Scholar
25. 1. Hannon E
    2. Dempster E
    3. Viana J
    4. Burrage J
    5. Smith AR
    6. Macdonald R
    7. St Clair D
    8. Mustard C
    9. Breen G
    10. Therman S
    11. Kaprio J
    12. Toulopoulou T
    13. Hulshoff Pol HE
    14. Bohlken MM
    15. Kahn RS
    16. Nenadic I
    17. Hultman CM
    18. Murray RM
    19. Collier DA
    20. Bass N
    21. Gurling H
    22. McQuillin A
    23. Schalkwyk L
    24. Mill J

    (2016a) An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation

    Genome Biology 17:176.

    https://doi.org/10.1186/s13059-016-1041-x

    • PubMed
    • Google Scholar
26. 1. Hannon E
    2. Spiers H
    3. Viana J
    4. Pidsley R
    5. Burrage J
    6. Murphy TM
    7. Troakes C
    8. Turecki G
    9. O'Donovan MC
    10. Schalkwyk LC
    11. Bray NJ
    12. Mill J

    (2016b) Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci

    Nature Neuroscience 19:48–54.

    https://doi.org/10.1038/nn.4182

    • PubMed
    • Google Scholar
27. 1. Hannon E
    2. Weedon M
    3. Bray N
    4. O'Donovan M
    5. Mill J

    (2017) Pleiotropic effects of Trait-Associated genetic variation on DNA methylation: utility for refining GWAS loci

    The American Journal of Human Genetics 100:954–959.

    https://doi.org/10.1016/j.ajhg.2017.04.013

    • PubMed
    • Google Scholar
28. 1. Hannon E
    2. Gorrie-Stone TJ
    3. Smart MC
    4. Burrage J
    5. Hughes A
    6. Bao Y
    7. Kumari M
    8. Schalkwyk LC
    9. Mill J

    (2018a) Leveraging DNA-Methylation Quantitative-Trait loci to characterize the relationship between methylomic variation, gene expression, and complex traits

    The American Journal of Human Genetics 103:654–665.

    https://doi.org/10.1016/j.ajhg.2018.09.007

    • PubMed
    • Google Scholar
29. 1. Hannon E
    2. Knox O
    3. Sugden K
    4. Burrage J
    5. Wong CCY
    6. Belsky DW
    7. Corcoran DL
    8. Arseneault L
    9. Moffitt TE
    10. Caspi A
    11. Mill J

    (2018b) Characterizing genetic and environmental influences on variable DNA methylation using monozygotic and dizygotic twins

    PLOS Genetics 14:e1007544.

    https://doi.org/10.1371/journal.pgen.1007544

    • PubMed
    • Google Scholar
30. 1. Hannon E
    2. Schendel D
    3. Ladd-Acosta C
    4. Grove J
    5. Hansen CS
    6. Andrews SV
    7. Hougaard DM
    8. Bresnahan M
    9. Mors O
    10. Hollegaard MV
    11. Bækvad-Hansen M
    12. Hornig M
    13. Mortensen PB
    14. Børglum AD
    15. Werge T
    16. Pedersen MG
    17. Nordentoft M
    18. Buxbaum J
    19. Daniele Fallin M
    20. Bybjerg-Grauholm J
    21. Reichenberg A
    22. Mill J
    23. iPSYCH-Broad ASD Group

    (2018c) Elevated polygenic burden for autism is associated with differential DNA methylation at birth

    Genome Medicine 10:19.

    https://doi.org/10.1186/s13073-018-0527-4

    • PubMed
    • Google Scholar
31. 1. Hannon E
    2. Marzi SJ
    3. Schalkwyk LS
    4. Mill J

    (2019a) Genetic risk variants for brain disorders are enriched in cortical H3K27ac domains

    Molecular Brain 12:e0429-4.

    https://doi.org/10.1186/s13041-019-0429-4

    • Google Scholar
32. 1. Hannon E
    2. Schendel D
    3. Ladd-Acosta C
    4. Grove J
    5. Hansen CS
    6. Hougaard DM
    7. Bresnahan M
    8. Mors O
    9. Hollegaard MV
    10. Bækvad-Hansen M
    11. Hornig M
    12. Mortensen PB
    13. Børglum AD
    14. Werge T
    15. Pedersen MG
    16. Nordentoft M
    17. Buxbaum JD
    18. Daniele Fallin M
    19. Bybjerg-Grauholm J
    20. Reichenberg A
    21. Mill J

    (2019b) Variable DNA methylation in neonates mediates the association between prenatal smoking and birth weight

    Philosophical Transactions of the Royal Society B: Biological Sciences 374:20180120.

    https://doi.org/10.1098/rstb.2018.0120

    • Google Scholar
33. Software

    1. Hannon E

    (2021) SCZEWAS, version swh:1:rev:006e92b11dbd3eb7e75dcc173853010fa93461a5

    Software Heritage.

    https://archive.softwareheritage.org/swh:1:dir:1f680bc713578103c59a629381ad3d5535d31c20;origin=https://github.com/ejh243/SCZEWAS/;visit=swh:1:snp:553287d336855c79e54e5b86bf4f0343c49e57c8;anchor=swh:1:rev:006e92b11dbd3eb7e75dcc173853010fa93461a5/
34. 1. Hannum G
    2. Guinney J
    3. Zhao L
    4. Zhang L
    5. Hughes G
    6. Sadda S
    7. Klotzle B
    8. Bibikova M
    9. Fan JB
    10. Gao Y
    11. Deconde R
    12. Chen M
    13. Rajapakse I
    14. Friend S
    15. Ideker T
    16. Zhang K

    (2013) Genome-wide methylation profiles reveal quantitative views of human aging rates

    Molecular Cell 49:359–367.

    https://doi.org/10.1016/j.molcel.2012.10.016

    • PubMed
    • Google Scholar
35. 1. Hilker R
    2. Helenius D
    3. Fagerlund B
    4. Skytthe A
    5. Christensen K
    6. Werge TM
    7. Nordentoft M
    8. Glenthøj B

    (2018) Heritability of schizophrenia and schizophrenia spectrum based on the nationwide danish twin register

    Biological Psychiatry 83:492–498.

    https://doi.org/10.1016/j.biopsych.2017.08.017

    • PubMed
    • Google Scholar
36. 1. Horvath S

    (2013) DNA methylation age of human tissues and cell types

    Genome Biology 14:R115.

    https://doi.org/10.1186/gb-2013-14-10-r115

    • PubMed
    • Google Scholar
37. 1. Houseman EA
    2. Accomando WP
    3. Koestler DC
    4. Christensen BC
    5. Marsit CJ
    6. Nelson HH
    7. Wiencke JK
    8. Kelsey KT

    (2012) DNA methylation arrays as surrogate measures of cell mixture distribution

    BMC Bioinformatics 13:86.

    https://doi.org/10.1186/1471-2105-13-86

    • PubMed
    • Google Scholar
38. 1. International Schizophrenia Consortium

    (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia

    Nature 455:237–241.

    https://doi.org/10.1038/nature07239

    • PubMed
    • Google Scholar
39. 1. Jaffe AE
    2. Gao Y
    3. Deep-Soboslay A
    4. Tao R
    5. Hyde TM
    6. Weinberger DR
    7. Kleinman JE

    (2016) Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex

    Nature Neuroscience 19:40–47.

    https://doi.org/10.1038/nn.4181

    • PubMed
    • Google Scholar
40. 1. Jongsma HE
    2. Gayer-Anderson C
    3. Lasalvia A
    4. Quattrone D
    5. Mulè A
    6. Szöke A
    7. Selten JP
    8. Turner C
    9. Arango C
    10. Tarricone I
    11. Berardi D
    12. Tortelli A
    13. Llorca PM
    14. de Haan L
    15. Bobes J
    16. Bernardo M
    17. Sanjuán J
    18. Santos JL
    19. Arrojo M
    20. Del-Ben CM
    21. Menezes PR
    22. Velthorst E
    23. Murray RM
    24. Rutten BP
    25. Jones PB
    26. van Os J
    27. Morgan C
    28. Kirkbride JB

    (2018) Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry 75:36–46.

    https://doi.org/10.1001/jamapsychiatry.2017.3554

    • PubMed
    • Google Scholar
41. 1. Karageorgiou V
    2. Milas GP
    3. Michopoulos I

    (2019) Neutrophil-to-lymphocyte ratio in schizophrenia: a systematic review and meta-analysis

    Schizophrenia Research 206:4–12.

    https://doi.org/10.1016/j.schres.2018.12.017

    • PubMed
    • Google Scholar
42. 1. Kennedy JL
    2. Altar CA
    3. Taylor DL
    4. Degtiar I
    5. Hornberger JC

    (2014) The social and economic burden of treatment-resistant schizophrenia: a systematic literature review

    International Clinical Psychopharmacology 29:63–76.

    https://doi.org/10.1097/YIC.0b013e32836508e6

    • PubMed
    • Google Scholar
43. 1. Kinoshita M
    2. Numata S
    3. Tajima A
    4. Ohi K
    5. Hashimoto R
    6. Shimodera S
    7. Imoto I
    8. Takeda M
    9. Ohmori T

    (2014) Aberrant DNA methylation of blood in schizophrenia by adjusting for estimated cellular proportions

    NeuroMolecular Medicine 16:697–703.

    https://doi.org/10.1007/s12017-014-8319-5

    • PubMed
    • Google Scholar
44. 1. Koestler DC
    2. Christensen B
    3. Karagas MR
    4. Marsit CJ
    5. Langevin SM
    6. Kelsey KT
    7. Wiencke JK
    8. Houseman EA

    (2013) Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis

    Epigenetics 8:816–826.

    https://doi.org/10.4161/epi.25430

    • PubMed
    • Google Scholar
45. 1. Kowalec K
    2. Hannon E
    3. Mansell G
    4. Burrage J
    5. Ori APS
    6. Ophoff RA
    7. Mill J
    8. Sullivan PF

    (2019) Methylation age acceleration does not predict mortality in schizophrenia

    Translational Psychiatry 9:157.

    https://doi.org/10.1038/s41398-019-0489-3

    • PubMed
    • Google Scholar
46. 1. Le-Niculescu H
    2. Balaraman Y
    3. Patel S
    4. Tan J
    5. Sidhu K
    6. Jerome RE
    7. Edenberg HJ
    8. Kuczenski R
    9. Geyer MA
    10. Nurnberger JI
    11. Faraone SV
    12. Tsuang MT
    13. Niculescu AB

    (2007) Towards understanding the schizophrenia code: an expanded convergent functional genomics approach

    American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B:129–158.

    https://doi.org/10.1002/ajmg.b.30481

    • PubMed
    • Google Scholar
47. 1. Levine ME
    2. Lu AT
    3. Quach A
    4. Chen BH
    5. Assimes TL
    6. Bandinelli S
    7. Hou L
    8. Baccarelli AA
    9. Stewart JD
    10. Li Y
    11. Whitsel EA
    12. Wilson JG
    13. Reiner AP
    14. Aviv A
    15. Lohman K
    16. Liu Y
    17. Ferrucci L
    18. Horvath S

    (2018) An epigenetic biomarker of aging for lifespan and healthspan

    Aging 10:573–591.

    https://doi.org/10.18632/aging.101414

    • PubMed
    • Google Scholar
48. 1. Mansell G
    2. Gorrie-Stone TJ
    3. Bao Y
    4. Kumari M
    5. Schalkwyk LS
    6. Mill J
    7. Hannon E

    (2019) Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array

    BMC Genomics 20:366.

    https://doi.org/10.1186/s12864-019-5761-7

    • PubMed
    • Google Scholar
49. 1. Marioni RE
    2. McRae AF
    3. Bressler J
    4. Colicino E
    5. Hannon E
    6. Li S
    7. Prada D
    8. Smith JA
    9. Trevisi L
    10. Tsai PC
    11. Vojinovic D
    12. Simino J
    13. Levy D
    14. Liu C
    15. Mendelson M
    16. Satizabal CL
    17. Yang Q
    18. Jhun MA
    19. Kardia SLR
    20. Zhao W
    21. Bandinelli S
    22. Ferrucci L
    23. Hernandez DG
    24. Singleton AB
    25. Harris SE
    26. Starr JM
    27. Kiel DP
    28. McLean RR
    29. Just AC
    30. Schwartz J
    31. Spiro A
    32. Vokonas P
    33. Amin N
    34. Ikram MA
    35. Uitterlinden AG
    36. van Meurs JBJ
    37. Spector TD
    38. Steves C
    39. Baccarelli AA
    40. Bell JT
    41. van Duijn CM
    42. Fornage M
    43. Hsu YH
    44. Mill J
    45. Mosley TH
    46. Seshadri S
    47. Deary IJ

    (2018) Meta-analysis of epigenome-wide association studies of cognitive abilities

    Molecular Psychiatry 23:2133–2144.

    https://doi.org/10.1038/s41380-017-0008-y

    • PubMed
    • Google Scholar
50. 1. Maunakea AK
    2. Nagarajan RP
    3. Bilenky M
    4. Ballinger TJ
    5. D'Souza C
    6. Fouse SD
    7. Johnson BE
    8. Hong C
    9. Nielsen C
    10. Zhao Y
    11. Turecki G
    12. Delaney A
    13. Varhol R
    14. Thiessen N
    15. Shchors K
    16. Heine VM
    17. Rowitch DH
    18. Xing X
    19. Fiore C
    20. Schillebeeckx M
    21. Jones SJ
    22. Haussler D
    23. Marra MA
    24. Hirst M
    25. Wang T
    26. Costello JF

    (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters

    Nature 466:253–257.

    https://doi.org/10.1038/nature09165

    • PubMed
    • Google Scholar
51. 1. Maurano MT
    2. Humbert R
    3. Rynes E
    4. Thurman RE
    5. Haugen E
    6. Wang H
    7. Reynolds AP
    8. Sandstrom R
    9. Qu H
    10. Brody J
    11. Shafer A
    12. Neri F
    13. Lee K
    14. Kutyavin T
    15. Stehling-Sun S
    16. Johnson AK
    17. Canfield TK
    18. Giste E
    19. Diegel M
    20. Bates D
    21. Hansen RS
    22. Neph S
    23. Sabo PJ
    24. Heimfeld S
    25. Raubitschek A
    26. Ziegler S
    27. Cotsapas C
    28. Sotoodehnia N
    29. Glass I
    30. Sunyaev SR
    31. Kaul R
    32. Stamatoyannopoulos JA

    (2012) Systematic localization of common disease-associated variation in regulatory DNA

    Science 337:1190–1195.

    https://doi.org/10.1126/science.1222794

    • PubMed
    • Google Scholar
52. 1. Mazza MG
    2. Lucchi S
    3. Rossetti A
    4. Clerici M

    (2020) Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio in non-affective psychosis: a meta-analysis and systematic review

    The World Journal of Biological Psychiatry 21:326–338.

    https://doi.org/10.1080/15622975.2019.1583371

    • PubMed
    • Google Scholar
53. 1. McClave AK
    2. McKnight-Eily LR
    3. Davis SP
    4. Dube SR

    (2010) Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 national health interview survey

    American Journal of Public Health 100:2464–2472.

    https://doi.org/10.2105/AJPH.2009.188136

    • PubMed
    • Google Scholar
54. 1. McGuffin P
    2. Farmer A
    3. Harvey I

    (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. development and reliability of the OPCRIT system

    Archives of General Psychiatry 48:764–770.

    https://doi.org/10.1001/archpsyc.1991.01810320088015

    • PubMed
    • Google Scholar
55. 1. Mill J
    2. Heijmans BT

    (2013) From promises to practical strategies in epigenetic epidemiology

    Nature Reviews Genetics 14:585–594.

    https://doi.org/10.1038/nrg3405

    • PubMed
    • Google Scholar
56. 1. Montano C
    2. Taub MA
    3. Jaffe A
    4. Briem E
    5. Feinberg JI
    6. Trygvadottir R
    7. Idrizi A
    8. Runarsson A
    9. Berndsen B
    10. Gur RC
    11. Moore TM
    12. Perry RT
    13. Fugman D
    14. Sabunciyan S
    15. Yolken RH
    16. Hyde TM
    17. Kleinman JE
    18. Sobell JL
    19. Pato CN
    20. Pato MT
    21. Go RC
    22. Nimgaonkar V
    23. Weinberger DR
    24. Braff D
    25. Gur RE
    26. Fallin MD
    27. Feinberg AP

    (2016) Association of DNA methylation differences with schizophrenia in an Epigenome-Wide association study

    JAMA Psychiatry 73:506–514.

    https://doi.org/10.1001/jamapsychiatry.2016.0144

    • PubMed
    • Google Scholar
57. 1. Moody G
    2. Miller BJ

    (2018) Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis

    Psychiatry Research 260:307–312.

    https://doi.org/10.1016/j.psychres.2017.11.086

    • PubMed
    • Google Scholar
58. 1. Morris DW
    2. Pearson RD
    3. Cormican P
    4. Kenny EM
    5. O'Dushlaine CT
    6. Perreault LP
    7. Giannoulatou E
    8. Tropea D
    9. Maher BS
    10. Wormley B
    11. Kelleher E
    12. Fahey C
    13. Molinos I
    14. Bellini S
    15. Pirinen M
    16. Strange A
    17. Freeman C
    18. Thiselton DL
    19. Elves RL
    20. Regan R
    21. Ennis S
    22. Dinan TG
    23. McDonald C
    24. Murphy KC
    25. O'Callaghan E
    26. Waddington JL
    27. Walsh D
    28. O'Donovan M
    29. Grozeva D
    30. Craddock N
    31. Stone J
    32. Scolnick E
    33. Purcell S
    34. Sklar P
    35. Coe B
    36. Eichler EE
    37. Ophoff R
    38. Buizer J
    39. Szatkiewicz J
    40. Hultman C
    41. Sullivan P
    42. Gurling H
    43. Mcquillin A
    44. St Clair D
    45. Rees E
    46. Kirov G
    47. Walters J
    48. Blackwood D
    49. Johnstone M
    50. Donohoe G
    51. O'Neill FA
    52. Kendler KS
    53. Gill M
    54. Riley BP
    55. Spencer CC
    56. Corvin A
    57. International Schizophrenia Consortium, SGENE+ Consortium
    58. Wellcome Trust Case Control Consortium 2

    (2014) An inherited duplication at the gene p21 Protein-Activated kinase 7 (PAK7) is a risk factor for psychosis

    Human Molecular Genetics 23:3316–3326.

    https://doi.org/10.1093/hmg/ddu025

    • PubMed
    • Google Scholar
59. 1. Murphy TM
    2. Mill J

    (2014) Epigenetics in health and disease: heralding the EWAS era

    The Lancet 383:1952–1954.

    https://doi.org/10.1016/S0140-6736(14)60269-5

    • PubMed
    • Google Scholar
60. 1. Myles N
    2. Newall HD
    3. Curtis J
    4. Nielssen O
    5. Shiers D
    6. Large M

    (2012) Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis

    The Journal of Clinical Psychiatry 73:468–475.

    https://doi.org/10.4088/JCP.11r07222

    • PubMed
    • Google Scholar
61. 1. Núñez C
    2. Stephan-Otto C
    3. Usall J
    4. Bioque M
    5. Lobo A
    6. González-Pinto A
    7. Pina-Camacho L
    8. Vieta E
    9. Castro-Fornieles J
    10. Rodriguez-Jimenez R
    11. Butjosa A
    12. Janssen J
    13. Cabrera B
    14. Parellada M
    15. Bernardo M
    16. PEPs group

    (2019) Neutrophil count is associated with reduced gray matter and enlarged ventricles in First-Episode psychosis

    Schizophrenia Bulletin 45:846–858.

    https://doi.org/10.1093/schbul/sby113

    • PubMed
    • Google Scholar
62. 1. O'Dushlaine C
    2. Kenny E
    3. Heron E
    4. Donohoe G
    5. Gill M
    6. Morris D
    7. Corvin A
    8. International Schizophrenia Consortium

    (2011) Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility

    Molecular Psychiatry 16:286–292.

    https://doi.org/10.1038/mp.2010.7

    • PubMed
    • Google Scholar
63. 1. Pardiñas AF
    2. Holmans P
    3. Pocklington AJ
    4. Escott-Price V
    5. Ripke S
    6. Carrera N
    7. Legge SE
    8. Bishop S
    9. Cameron D
    10. Hamshere ML
    11. Han J
    12. Hubbard L
    13. Lynham A
    14. Mantripragada K
    15. Rees E
    16. MacCabe JH
    17. McCarroll SA
    18. Baune BT
    19. Breen G
    20. Byrne EM
    21. Dannlowski U
    22. Eley TC
    23. Hayward C
    24. Martin NG
    25. McIntosh AM
    26. Plomin R
    27. Porteous DJ
    28. Wray NR
    29. Caballero A
    30. Geschwind DH
    31. Huckins LM
    32. Ruderfer DM
    33. Santiago E
    34. Sklar P
    35. Stahl EA
    36. Won H
    37. Agerbo E
    38. Als TD
    39. Andreassen OA
    40. Bækvad-Hansen M
    41. Mortensen PB
    42. Pedersen CB
    43. Børglum AD
    44. Bybjerg-Grauholm J
    45. Djurovic S
    46. Durmishi N
    47. Pedersen MG
    48. Golimbet V
    49. Grove J
    50. Hougaard DM
    51. Mattheisen M
    52. Molden E
    53. Mors O
    54. Nordentoft M
    55. Pejovic-Milovancevic M
    56. Sigurdsson E
    57. Silagadze T
    58. Hansen CS
    59. Stefansson K
    60. Stefansson H
    61. Steinberg S
    62. Tosato S
    63. Werge T
    64. Collier DA
    65. Rujescu D
    66. Kirov G
    67. Owen MJ
    68. O'Donovan MC
    69. Walters JTR
    70. GERAD1 Consortium
    71. CRESTAR Consortium

    (2018) Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection

    Nature Genetics 50:381–389.

    https://doi.org/10.1038/s41588-018-0059-2

    • PubMed
    • Google Scholar
64. 1. Park HJ
    2. Kim JW
    3. Lee SK
    4. Kim SK
    5. Park JK
    6. Cho AR
    7. Chung JH
    8. Song JY

    (2011) Association between the SLC6A12 gene and negative symptoms of schizophrenia in a korean population

    Psychiatry Research 189:478–479.

    https://doi.org/10.1016/j.psychres.2011.01.023

    • PubMed
    • Google Scholar
65. 1. Pidsley R
    2. Y Wong CC
    3. Volta M
    4. Lunnon K
    5. Mill J
    6. Schalkwyk LC

    (2013) A data-driven approach to preprocessing Illumina 450K methylation array data

    BMC Genomics 14:293.

    https://doi.org/10.1186/1471-2164-14-293

    • PubMed
    • Google Scholar
66. 1. Pidsley R
    2. Viana J
    3. Hannon E
    4. Spiers H
    5. Troakes C
    6. Al-Saraj S
    7. Mechawar N
    8. Turecki G
    9. Schalkwyk LC
    10. Bray NJ
    11. Mill J

    (2014) Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia

    Genome Biology 15:483.

    https://doi.org/10.1186/s13059-014-0483-2

    • PubMed
    • Google Scholar
67. 1. Psychiatric GWAS Consortium Bipolar Disorder Working Group

    (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4

    Nature Genetics 43:977–983.

    https://doi.org/10.1038/ng.943

    • PubMed
    • Google Scholar
68. 1. Purcell SM
    2. Wray NR
    3. Stone JL
    4. Visscher PM
    5. O'Donovan MC
    6. Sullivan PF
    7. Sklar P
    8. International Schizophrenia Consortium

    (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

    Nature 460:748–752.

    https://doi.org/10.1038/nature08185

    • PubMed
    • Google Scholar
69. 1. Quattrone D
    2. Di Forti M
    3. Gayer-Anderson C
    4. Ferraro L
    5. Jongsma HE
    6. Tripoli G
    7. La Cascia C
    8. La Barbera D
    9. Tarricone I
    10. Berardi D
    11. Szöke A
    12. Arango C
    13. Lasalvia A
    14. Tortelli A
    15. Llorca PM
    16. de Haan L
    17. Velthorst E
    18. Bobes J
    19. Bernardo M
    20. Sanjuán J
    21. Santos JL
    22. Arrojo M
    23. Del-Ben CM
    24. Menezes PR
    25. Selten JP
    26. Jones PB
    27. Kirkbride JB
    28. Richards AL
    29. O'Donovan MC
    30. Sham PC
    31. Vassos E
    32. Rutten BP
    33. van Os J
    34. Morgan C
    35. Lewis CM
    36. Murray RM
    37. Reininghaus U
    38. EU-GEI WP2 Group

    (2019) Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study

    Psychological Medicine 49:1378–1391.

    https://doi.org/10.1017/S0033291718002131

    • PubMed
    • Google Scholar
70. 1. Rakyan VK
    2. Down TA
    3. Balding DJ
    4. Beck S

    (2011) Epigenome-wide association studies for common human diseases

    Nature Reviews Genetics 12:529–541.

    https://doi.org/10.1038/nrg3000

    • PubMed
    • Google Scholar
71. 1. Relton CL
    2. Davey Smith G

    (2010) Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment

    PLOS Medicine 7:e1000356.

    https://doi.org/10.1371/journal.pmed.1000356

    • PubMed
    • Google Scholar
72. 1. Ripke S
    2. Sanders A
    3. Kendler K
    4. Levinson D
    5. Sklar P
    6. Genome-Wide SP
    7. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium

    (2011) Genome-wide association study identifies five new schizophrenia loci

    Nature Genetics 43:969–U977.

    https://doi.org/10.1038/ng.940

    • PubMed
    • Google Scholar
73. 1. Ripke S
    2. Neale B
    3. Corvin A
    4. Walters J
    5. Farh K
    6. Consor WTC
    7. Schizophrenia Working Group of the Psychiatric Genomics Consortium

    (2014) Biological insights from 108 schizophrenia-associated genetic loci

    Nature 511:421–427.

    https://doi.org/10.1038/nature13595

    • PubMed
    • Google Scholar
74. 1. Schwarzer G

    (2007)

    Meta: an R package for meta-analysis

    R News 7:40–45.

    • Google Scholar
75. Report

    1. Spitzer R
    2. Endicott J

    (1977)

    The Schedule for Affective Disorders and Schizophrenia, Lifetime Version 

    New York State Psychiatric Institute.

    • Google Scholar
76. 1. Steiner J
    2. Frodl T
    3. Schiltz K
    4. Dobrowolny H
    5. Jacobs R
    6. Fernandes BS
    7. Guest PC
    8. Meyer-Lotz G
    9. Borucki K
    10. Bahn S
    11. Bogerts B
    12. Falkai P
    13. Bernstein H-G

    (2019) Innate immune cells and C-Reactive protein in acute First-Episode psychosis and schizophrenia: relationship to psychopathology and treatment

    Schizophrenia Bulletin 13:363–373.

    https://doi.org/10.1093/schbul/sbz068

    • Google Scholar
77. 1. Sugden K
    2. Hannon EJ
    3. Arseneault L
    4. Belsky DW
    5. Broadbent JM
    6. Corcoran DL
    7. Hancox RJ
    8. Houts RM
    9. Moffitt TE
    10. Poulton R
    11. Prinz JA
    12. Thomson WM
    13. Williams BS
    14. Wong CCY
    15. Mill J
    16. Caspi A

    (2019) Establishing a generalized polyepigenetic biomarker for tobacco smoking

    Translational Psychiatry 9:92.

    https://doi.org/10.1038/s41398-019-0430-9

    • PubMed
    • Google Scholar
78. 1. Sullivan PF
    2. Kendler KS
    3. Neale MC

    (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies

    Archives of General Psychiatry 60:1187–1192.

    https://doi.org/10.1001/archpsyc.60.12.1187

    • PubMed
    • Google Scholar
79. 1. van der Werf M
    2. Hanssen M
    3. Köhler S
    4. Verkaaik M
    5. Verhey FR
    6. van Winkel R
    7. van Os J
    8. Allardyce J
    9. RISE Investigators

    (2014) Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia

    Psychological Medicine 44:9–16.

    https://doi.org/10.1017/S0033291712002796

    • PubMed
    • Google Scholar
80. 1. van Iterson M
    2. van Zwet EW
    3. Heijmans BT
    4. BIOS Consortium

    (2017) Controlling Bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution

    Genome Biology 18:19.

    https://doi.org/10.1186/s13059-016-1131-9

    • PubMed
    • Google Scholar
81. 1. Viana J
    2. Hannon E
    3. Dempster E
    4. Pidsley R
    5. Macdonald R
    6. Knox O
    7. Spiers H
    8. Troakes C
    9. Al-Saraj S
    10. Turecki G
    11. Schalkwyk LC
    12. Mill J

    (2017) Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions

    Human Molecular Genetics 16:210–225.

    https://doi.org/10.1093/hmg/ddw373

    • Google Scholar
82. 1. Wagner JR
    2. Busche S
    3. Ge B
    4. Kwan T
    5. Pastinen T
    6. Blanchette M

    (2014) The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts

    Genome Biology 15:R37.

    https://doi.org/10.1186/gb-2014-15-2-r37

    • PubMed
    • Google Scholar
83. 1. Whiteford HA
    2. Degenhardt L
    3. Rehm J
    4. Baxter AJ
    5. Ferrari AJ
    6. Erskine HE
    7. Charlson FJ
    8. Norman RE
    9. Flaxman AD
    10. Johns N
    11. Burstein R
    12. Murray CJ
    13. Vos T

    (2013) Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010

    The Lancet 382:1575–1586.

    https://doi.org/10.1016/S0140-6736(13)61611-6

    • PubMed
    • Google Scholar
84. 1. Wockner LF
    2. Noble EP
    3. Lawford BR
    4. Young RM
    5. Morris CP
    6. Whitehall VL
    7. Voisey J

    (2014) Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients

    Translational Psychiatry 4:e339.

    https://doi.org/10.1038/tp.2013.111

    • PubMed
    • Google Scholar
85. 1. Yang J
    2. Lee SH
    3. Goddard ME
    4. Visscher PM

    (2011) GCTA: a tool for genome-wide complex trait analysis

    The American Journal of Human Genetics 88:76–82.

    https://doi.org/10.1016/j.ajhg.2010.11.011

    • PubMed
    • Google Scholar
86. 1. Zhang Q
    2. Vallerga CL
    3. Walker RM
    4. Lin T
    5. Henders AK
    6. Montgomery GW
    7. He J
    8. Fan D
    9. Fowdar J
    10. Kennedy M
    11. Pitcher T
    12. Pearson J
    13. Halliday G
    14. Kwok JB
    15. Hickie I
    16. Lewis S
    17. Anderson T
    18. Silburn PA
    19. Mellick GD
    20. Harris SE
    21. Redmond P
    22. Murray AD
    23. Porteous DJ
    24. Haley CS
    25. Evans KL
    26. McIntosh AM
    27. Yang J
    28. Gratten J
    29. Marioni RE
    30. Wray NR
    31. Deary IJ
    32. McRae AF
    33. Visscher PM

    (2019) Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing

    Genome Medicine 11:54.

    https://doi.org/10.1186/s13073-019-0667-1

    • PubMed
    • Google Scholar

Author details

1. Eilis Hannon

   University of Exeter Medical School, University of Exeter, Barrack Road, Exeter, United Kingdom

   Contribution

   Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-6840-072X

2. Emma L Dempster

   University of Exeter Medical School, University of Exeter, Barrack Road, Exeter, United Kingdom

   Contribution

   Resources, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

3. Georgina Mansell

   University of Exeter Medical School, University of Exeter, Barrack Road, Exeter, United Kingdom

   Contribution

   Data curation, Formal analysis, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-2620-1786

4. Joe Burrage

   University of Exeter Medical School, University of Exeter, Barrack Road, Exeter, United Kingdom

   Contribution

   Resources, Data curation, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

5. Nick Bass

   Division of Psychiatry, University College London, London, United Kingdom

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

6. Marc M Bohlken

   Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan, Utrecht, Netherlands

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

7. Aiden Corvin

   Department of Psychiatry and Neuropsychiatric Genetics Research Group, Trinity Translational Medicine Institute, Trinity College Dublin, St. James Hospital, Dublin, Ireland

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

8. Charles J Curtis

   1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
   2. NIHR BioResource Centre Maudsley, South London and Maudsley NHS Foundation Trust (SLaM), King’s College London, London, United Kingdom

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

9. David Dempster

   Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

10. Marta Di Forti

    1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
    2. South London and Maudsley NHS Mental Health Foundation Trust, London, United Kingdom
    3. National Institute for Health Research (NIHR), Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    M Di Forti reports personal fees from Janssen, outside the submitted work.

11. Timothy G Dinan

    APC Microbiome Ireland, University College Cork, Cork, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

12. Gary Donohoe

    Centre for Neuroimaging and Cognitive Genomics (NICOG), School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Galway, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

13. Fiona Gaughran

    1. Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
    2. National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    Fiona Gaughran has received honoraria from Lundbeck, Otsuka, and Sunovion. She has a family member with professional links to Lilly and GSK, including shares.

14. Michael Gill

    Department of Psychiatry and Neuropsychiatric Genetics Research Group, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

15. Amy Gillespie

    1. Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
    2. Department of Psychiatry, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

16. Cerisse Gunasinghe

    Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

17. Hilleke E Hulshoff

    Department of Psychiatry, University Medical Center Utrecht, Utrecht, Netherlands

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

18. Christina M Hultman

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

19. Viktoria Johansson

    1. Department of Medical Epidemiology and Biostatistics Sweden, Karolinska Institutet, Stockholm, Sweden
    2. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

20. René S Kahn

    1. Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
    2. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

21. Jaakko Kaprio

    1. Institute for Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland
    2. Department of Public Health, University of Helsinki, Helsinki, Finland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-3716-2455

22. Gunter Kenis

    Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

23. Kaarina Kowalec

    1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    2. College of Pharmacy, University of Manitoba, Winnipeg, Canada

    Contribution

    Resources, Writing - review and editing

    Competing interests

    Kaarina Kowalec has consulted with Emerald Lake Safety Ltd. (2017-2018) and has received speaker honoraria from Biogen/Fraser Health Multiple Sclerosis Clinic (2018). Both are unrelated to the work published here.

24. James MacCabe

    Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    James MacCabe has received research funding from H Lundbeck.

25. Colm McDonald

    Centre for Neuroimaging and Cognitive Genomics (NICOG), School of Medicine, National University of Ireland Galway, Galway, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

26. Andrew McQuillin

    1. Division of Psychiatry, University College London, London, United Kingdom
    2. Division of Psychiatry, University College London, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0003-1567-2240

27. Derek W Morris

    Centre for Neuroimaging and Cognitive Genomics (NICOG), School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Galway, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

28. Kieran C Murphy

    Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

29. Colette J Mustard

    Division of Biomedical Sciences, Institute of Health Research and Innovation, University of the Highlands and Islands, Inverness, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0001-5834-2765

30. Igor Nenadic

    1. Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany
    2. Department of Psychiatry and Psychotherapy, Philipps University Marburg/ Marburg University Hospital UKGM, Marburg, Germany

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

31. Michael C O'Donovan

    MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    Michael C O'Donovan is supported by a collaborative research grant from Takeda Pharmaceuticals. Takeda played no part in the conception, design, implementation, or interpretation of this study.

32. Diego Quattrone

    1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
    2. South London and Maudsley NHS Mental Health Foundation Trust, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

33. Alexander L Richards

    MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

34. Bart PF Rutten

    Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-9834-6346

35. David St Clair

    The Institute of Medical Sciences, Univeristy of Aberdeen, Aberdeen, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

36. Sebastian Therman

    Department of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0001-9407-4905

37. Timothea Toulopoulou

    Department of Psychology and National Magnetic Resonance Research Center (UMRAM), Aysel Sabuncu Brain Research Centre (ASBAM), Bilkent University, Ankara, Turkey

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

38. Jim Van Os

    Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

39. John L Waddington

    Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

40. Wellcome Trust Case Control Consortium (WTCCC)

41. CRESTAR consortium

42. Patrick Sullivan

    1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    2. Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, United States

    Contribution

    Resources, Writing - review and editing

    Competing interests

    PF Sullivan reports the following potentially competing financial interests. Current: Lundbeck (advisory committee, grant recipient). Past three years: Pfizer (scientific advisory board).

43. Evangelos Vassos

    Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

44. Gerome Breen

    1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
    2. NIHR BioResource Centre Maudsley, South London and Maudsley NHS Foundation Trust (SLaM), King’s College London, London, United Kingdom

    Contribution

    Resources, Funding acquisition, Writing - review and editing

    Competing interests

    No competing interests declared

45. David Andrew Collier

    Neuroscience Genetics, Eli Lilly and Company, Surrey, United Kingdom

    Contribution

    Resources, Funding acquisition, Writing - review and editing

    Competing interests

    David A Collier is a full time employee and stockholder of Eli Lilly and Company.

46. Robin M Murray

    Department of Psychosis Studies, Institute of Psychiatry, King’s College London, London, United Kingdom

    Contribution

    Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing - original draft, Project administration, Writing - review and editing

    Competing interests

    Robin M Murray reports personal fees from Janssen, Lundbeck, Sunovion, Recordati and Otsuka

47. Leonard S Schalkwyk

    School of Life Sciences, University of Essex, Colchester, United Kingdom

    Contribution

    Conceptualization, Resources, Funding acquisition, Methodology, Writing - review and editing

    Competing interests

    No competing interests declared

48. Jonathan Mill

    University of Exeter Medical School, University of Exeter, Barrack Road, Exeter, United Kingdom

    Contribution

    Conceptualization, Supervision, Funding acquisition, Methodology, Writing - original draft, Project administration, Writing - review and editing

    For correspondence

    j.mill@exeter.ac.uk

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0003-1115-3224

• 5,495

  Page views

• 531

  Downloads

• 56

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.